AngioDynamics (ANGO) FQ1 meets EPS expectations and beats on revenue. Oncology/Surgery sales...

|By:, SA News Editor

AngioDynamics (ANGO) FQ1 meets EPS expectations and beats on revenue. Oncology/Surgery sales were up 15% Y/Y due to a 105% Y/Y jump in NanoKnife System sales. Current quarter guidance was mixed, with the company saying it expects an EPS of $0.09 to $0.11 on revenues in the range of $55.5M to $57.5M, versus analysts expectations for $56M in sales and an EPS of $0.12. Separately, the company announces a $20M share buyback.